Although direct evidence for tetradioxin in ARDS is lacking, its dual targeting of SMARCD3 and TCN1 suggests it may regulate inflammatory and metabolic pathways pertinent to ARDS. This evidence concerns the gene TCN1 and acute respiratory distress syndrome.